American Association for Cancer Research
Browse
15357163mct160333t-sup-166859_1_supp_3666856_wdw4vq.png (32.76 kB)

Figure S4 from Identification and Validation of Compounds Selectively Killing Resistant Cancer: Delineating Cell Line–Specific Effects from P-Glycoprotein–Induced Toxicity

Download (32.76 kB)
figure
posted on 2023-04-03, 15:44 authored by András Füredi, Szilárd Tóth, Kornélia Szebényi, Veronika F.S. Pape, Dóra Türk, Nóra Kucsma, László Cervenak, József Tóvári, Gergely Szakács

Supplementary Figure 4. Treatment stoppage does not lead to the re-expression of Pgp. MESSA-Dx5 cells were first treated with NSC57969to induce Pgp-loss, and then were cultured in normal medium. Lack of Pgp-activity at passage 17 and 28 is demonstrated with the calcein assay.

Funding

Hungarian Academy of Sciences

ERC

National Research, Development and Innovation

History

ARTICLE ABSTRACT

Despite significant progress, resistance to chemotherapy is still the main reason why cancer remains a deadly disease. An attractive strategy is to target the collateral sensitivity of otherwise multidrug resistant (MDR) cancer. In this study, our aim was to catalog various compounds that were reported to elicit increased toxicity in P-glycoprotein (Pgp)–overexpressing MDR cells. We show that the activity of most of the serendipitously identified compounds reported to target MDR cells is in fact cell-line specific, and is not influenced significantly by the function of Pgp. In contrast, novel 8-hydroxyquinoline derivatives that we identify in the National Cancer Institute (NCI) drug repository possess a robust Pgp-dependent toxic activity across diverse cell lines. Pgp expression associated with the resistance of the doxorubicin-resistant Brca1−/−;p53−/− spontaneous mouse mammary carcinoma cells could be eliminated by a single treatment with NSC57969, suggesting that MDR-selective compounds can effectively revert the MDR phenotype of cells expressing Pgp at clinically relevant levels. The discovery of new MDR-selective compounds shows the potential of this emerging technology and highlights the 8-hydroxyquinoline scaffold as a promising starting point for the development of compounds targeting the Achilles heel of drug-resistant cancer. Mol Cancer Ther; 16(1); 45–56. ©2016 AACR.

Usage metrics

    Molecular Cancer Therapeutics

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC